Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
131I-anti-TLR5 monoclonal antibody is a **radioiodinated monoclonal antibody** targeting **Toll-like receptor 5 (TLR5)**, which is overexpressed in several cancers, particularly hepatocellular carcinoma. It is primarily investigated as a radiotracer for **molecular imaging and diagnosis** of TLR5-expressing tumors. The antibody is labeled with radioactive iodine-131 to allow specific detection and visualization of tumor tissue via non-invasive imaging. Preclinical studies have demonstrated high tumor uptake and selectivity in animal models, making it a promising diagnostic agent for tumors with elevated TLR5 expression[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 131I-anti-TLR5 monoclonal antibody.